HTG Molecular Diagnostics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

htgmolecular.com

Founded Year

1997

Stage

Loan | IPO

Total Raised

$71.28M

Market Cap

0.00B

Stock Price

0.57

Revenue

$0000 

About HTG Molecular Diagnostics

HTG Molecular Diagnostics provides instruments, reagents, and services for molecular profiling applications.

HTG Molecular Diagnostics Headquarter Location

3430 East Global Loop

Tucson, Arizona, 85706,

United States

877-289-2615

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing HTG Molecular Diagnostics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

HTG Molecular Diagnostics is included in 3 Expert Collections, including Medical Devices.

M

Medical Devices

8,154 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

76 items

Companies developing companion diagnostics and technology enabling the development of companion diagnostics. Tagged as #CompanionDx

H

Health IT

7,900 items

HTG Molecular Diagnostics Patents

HTG Molecular Diagnostics has filed 13 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genetics
  • Biotechnology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/8/2019

3/8/2022

Transcription factors, Molecular biology, Genetics, Clusters of differentiation, Proteins

Grant

Application Date

4/8/2019

Grant Date

3/8/2022

Title

Related Topics

Transcription factors, Molecular biology, Genetics, Clusters of differentiation, Proteins

Status

Grant

Latest HTG Molecular Diagnostics News

HTG Molecular Diagnostics to Participate in the H.C. Wainwright Global Investment Conference

May 17, 2022

Management will also be available for one-on-one virtual meetings. If you would like to request a meeting please register here . About HTG: HTG is accelerating precision medicine from diagnosis to treatment by harnessing the power of transcriptome-wide profiling to drive translational research, clinical diagnostics and targeted therapeutics across a variety of disease areas. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. For more information visit www.htgmolecular.com . HTG Investor Contact:

HTG Molecular Diagnostics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

HTG Molecular Diagnostics Rank

  • When was HTG Molecular Diagnostics founded?

    HTG Molecular Diagnostics was founded in 1997.

  • Where is HTG Molecular Diagnostics's headquarters?

    HTG Molecular Diagnostics's headquarters is located at 3430 East Global Loop, Tucson.

  • What is HTG Molecular Diagnostics's latest funding round?

    HTG Molecular Diagnostics's latest funding round is Loan.

  • How much did HTG Molecular Diagnostics raise?

    HTG Molecular Diagnostics raised a total of $71.28M.

  • Who are HTG Molecular Diagnostics's competitors?

    Competitors of HTG Molecular Diagnostics include Sirion Biotech, BioDot, Scienion, WaferGen Bio-systems, Gyros, Life Technologies Corporation, Zyomyx, NanoString Technologies, EnCoate, Helicos BioSciences and 24 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

P
ProteoPlex

Proteoplex is a spinout of Incyte Genomics and aims to provide the scientific community with key functional genomic and proteomic tools and services in the areas of Gene Expression, Protein Expression and Cell-Based Assays. The proteomics product addresses a major barrier in defining the function of proteins in cells; how to quickly and cheaply test thousands of samples for the presence of a particular set of proteins. This protein product will be closely followed by the launch of gene expression products to solve a similar barrier in the genomics market; how to quickly and cheaply interrogate thousands of samples against a defined set of important genes.

O
Ocimum Biosolutions

Ocimum Biosolutions is a life sciences RnD enabling company with three focus areas, BioIT (LIMS / Bioinformatics), BioMolecules, and BioResearch. Ocimum aims to deliver end to end genomic products and services out of three strategic locations worldwide, Indianapolis (United States), IJsselstien (The Netherlands), Hyderabad (India).

S
SideroGen

SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Shamrock Structures Logo
Shamrock Structures

Shamrock Structures is a structural proteomics company focused on assisting pharmaceutical and biotechnology clients reduce the time it takes to advance from protein targets to drugs by offering integrated services in structural proteomics including protein cloning, expression, purification and crystallization.

C
CAPE Technologies

CAPE Technologies, of South Portland created a practical immunoassay-based test kits for dioxin and dioxin-like PCBs. The kits provide near real time analysis in a simple field lab, at lower cost, with less equipment, and with fewer people, than conventional methods. CAPE's dioxin kit is the only rapid dioxin screening method accepted by the U.S. Environmental Protection Agency (EPA) for solid waste analysis. A third kit is also available for rapid field analysis of total PCBs. CAPE's kits are marketed by distributors in Australia, Japan, Italy, Taiwan, China, and Finland, and directly through its web site to the rest of the world. CAPE Technologies maintains local ties with the University of New England, the University of Southern Maine, and the University of Maine at Orono. Dr. Robert Harrison of Cape Elizabeth is co-founder and president.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.